Annette Fox

Dr. Annette Fox


Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 February 2022 in Viruses
Verified
Journal Article
Open access
PDF file
AFAnnette Fox
Annette Fox
LCLouise Carolan
Louise Carolan
VLVivian Leung
Vivian Leung
HPHoang Vu Mai Phuong
Hoang Vu Mai Phuong
AKArseniy Khvorov
Arseniy Khvorov
SSSheena Sullivan
Sheena Sullivan
Prior vaccination can alternately enhance or attenuate influenza vaccine immunogenicity and effectiveness. Analogously, we found that vaccine immunogenicity was enhanced by prior A(H3N2) virus infection among participants of the Ha Nam Cohort, Viet Nam, but was attenuated by prior vaccination among Australian Health Care Workers (HCWs) vaccinated in the same year. Here, we combined these studies to directly compare antibody titers against 35 A(H3N2) viruses spanning 1968–2018. Participants received licensed inactivated vaccines containing A/HongKong/4801/2014 (H3N2). The analysis was limited to participants aged 18–65 Y, and compared those exposed to A(H3N2) viruses circulating since 2009 by infection (Ha Nam) or vaccination (HCWs) to a reference group who had no recent A(H3N2) infection or vaccination (Ha Nam). Antibody responses were compared by fitting titer/titer-rise landscapes across strains, and by estimating titer ratios to the reference group of 2009–2018 viruses. Pre-vaccination, titers were lowest against 2009–2014 viruses among the reference (no recent exposure) group. Post-vaccination, titers were, on average, two-fold higher among participants with prior infection and two-fold lower among participants with 3–5 prior vaccinations compared to the reference group. Titer rise was negligible among participants with 3–5 prior vaccinations, poor among participants with 1–2 prior vaccinations, and equivalent or better among those with prior infection compared to the reference group. The enhancing effect of prior infection versus the incrementally attenuating effect of prior vaccinations suggests that these exposures may alternately promote and constrain the generation of memory that can be recalled by a new vaccine strain.

3 April 2026 in The Lancet Infectious Diseases
Verified
Journal Article
Open access
SSSheena G Sullivan
Sheena G Sullivan
XPXuan Ying Poh
Xuan Ying Poh
SSStephany Sanchez-Ovando
Stephany Sanchez-Ovando
AHA Jessica Hadiprodjo
A Jessica Hadiprodjo
LCLouise Carolan
Louise Carolan
AFAnnette Fox
Annette Fox
Egg-grown influenza vaccines can have low effectiveness against A(H3N2), especially among repeat vaccinees. Cell-grown and recombinant-haemagglutinin vaccines can overcome attenuation associated with egg-acquired adaptations, but it is uncertain whether they remain effective with repeated vaccination. Here, we aim to compare immune responses induced by egg-grown, cell-grown, and recombinant vaccines among frequent and infrequent vaccinees. We conducted a randomised, controlled, single-centre, double-blind, phase 4 clinical trial to assess whether high-dose (45 μg of each antigen) recombinant quadrivalent influenza vaccines (QIV-R) are more immunogenic than standard-dose (15 μg of each antigen) egg-grown (QIV-E) and cell-grown (QIV-C) vaccines. Adults aged 21-49 years with no contraindications to vaccination and no immunocompromising conditions were enrolled at the National Centre for Infectious Diseases, Singapore. Participants were stratified by the number of vaccines received in the preceding 5 years as infrequent (zero or one) and frequent (three or more) and randomly assigned 1:1:1 to receive a single dose of QIV-R, QIV-C, or QIV-E by intramuscular injection. Participants and outcome assessors were masked to group allocation until study completion. The primary outcome was geometric mean titre (GMT) against egg-grown and cell-grown A(H3N2) vaccine viruses at 14 days post-vaccination, estimated by linear regression adjusted for vaccination history and baseline titre and analysed in the per-protocol set. Safety data were collected and reviewed by the study team. This trial is registered with ClinicalTrials.gov (NCT05479370) and is complete. Between Oct 6, 2022, and March 31, 2023, we enrolled 366 adults. Pre-vaccination and post-vaccination serum pairs were available for 359 (n=120 QIV-R, n=119 QIV-C, n=120 QIV-E). Post-vaccination GMTs against cell-grown A(H3N2) were 2·9-fold higher (95% CI 2·2-3·8) following QIV-R (GMT 100, 95% CI 84-120) compared with QIV-C (35, 29-43; p<0·0001) or QIV-E (36, 29-43; p<0·0001). Adjusted GMTs were lower among frequent compared with infrequent vaccinees who received QIV-E (GMT 25, 95% CI 19-34 vs 50, 38-66) or QIV-C (24, 18-32 vs 53, 40-70) but were similar for frequent and infrequent vaccinees who received QIV-R (93, 70-120 vs 110, 84-150). Rates of adverse events were similar between QIV-E (three [3%] of 120), QIV-C (two [2%] of 119), and QIV-R (zero of 120). QIV-R induced greater A(H3N2)-reactive antibody titres than QIV-E or QIV-C and was equally immunogenic among frequent and infrequent vaccinees. Further work is needed to ascertain whether this gain is sustained with QIV-R vaccination over multiple seasons. Sanofi.